TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Colorectal Cancer Metastatic · Advanced Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
Contact: Study coordinator (Yuankai Shi, Doctor of Medicine) · syuankaipumc@126.com · 8610-67781331

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Colorectal Cancer Metastatic · Liver Metastases · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

New York, United States

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Colorectal Cancer · KRAS G12C Mutant Advanced Solid Tumors · Fulzerasib

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Advanced/Metastatic Solid Tumors · Colorectal Cancer · Gastric Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

La Jolla, United States · Los Angeles, United States